U.S., March 11 -- ClinicalTrials.gov registry received information related to the study (NCT07462260) titled 'Sildinafil in Pulmonary Hypertension-Rheumatic Chronic Valvular Disease(RCT)' on March 05.
Brief Summary: Pulmonary hypertension secondary to left heart disease is associated with increased morbidity and mortality, particularly in patients with rheumatic chronic valvular heart disease, which remains highly prevalent in low- and middle-income countries. These patients often present late with severe pulmonary hypertension, limiting surgical options and worsening outcomes. Sildenafil, a phosphodiesterase-5 inhibitor, has demonstrated benefit in various forms of pulmonary hypertension; however, its role in pulmonary hypertension second...